Open Orphan, the Dublin-listed pharmaceutical services company run by Cathal Friel, has announced that its hVIVO subsidiary has signed a £5 million contract with a European biotechnology company.
Under the terms of the contract, the European biotech company will test its intravenous antiviral candidate using the Hvivo human challenge study model for respiratory syncytial virus , an illness which affects the respiratory tract of children and at-risk adults. In severe cases it can...
Belgique Dernières Nouvelles, Belgique Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
La source: businessposthq - 🏆 8. / 71 Lire la suite »
La source: businessposthq - 🏆 8. / 71 Lire la suite »